Novel nanoscale vehicles for drug delivery
UCL pioneers the engineering of novel nanoscale drug delivery vehicles, which can be tuned to release a range of cargos.
Postnova Analytics reports on the recent investment by the Department of Chemistry at University College London (UCL) in an AF2000 Field Flow Fractionation System to assist them in their development of novel nanoscale vehicles for drug delivery.
UCL has pioneered the engineering of novel nanoscale drug delivery vehicles which can be tuned to release a range of cargos. The drug delivery system is based upon the synthesis of self-assembled spherical polymer vesicles known as polymersomes. Polymersomes are biocompatible and stable making them ideal for the development of drug delivery systems.
Paul Clarke, Managing Director of Postnova Analytics (UK) said: "Researchers at UCL purchased the Postnova AF2000 system to work on the purification and characterisation of polymersomes being synthesised for the treatment of several diseases including cancer, infections and neurological disorders. The project is part of a multidisciplinary effort aimed toward the design of personalised nanomedicines. We are delighted to provide UCL with an analytical tool that will assist them in their ground breaking work".
Guiseppe Battaglia, Professor of Molecular Bionics, within the Chemistry Department at UCL commented: “Having identified Field Flow Fractionation as the best technique to purify and characterise polymersomes we elected to purchase an AF2000 system from Postnova as it allows us to quantify the materials both in terms of size as well as shape. Such an effort is critical to both elucidate important structure/function relation, as well as to expedite the necessary quality control associated with clinical translation.
The Postnova AF2000 is a high performance Field Flow Fractionation (FFF) platform for separation of proteins, macromolecules and nanoparticles. Modular in design, the AF2000 incorporates the combined experience, expertise and technological advances from Postnova Analytics' nearly two decades of leadership in FFF. Incorporating a range of FFF modules in a single integrated system to provide universal separation, the AF2000 offers more flexibility, better performance and more robust results than any system before.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.